Cognitive Enhancement Research
BDNF, neuroplasticity, and anxiolytic mechanisms in nootropic peptide research
What Is This Category?
Semax and Selank are Soviet-era synthetic peptides developed in Russia during the 1970s–80s and still prescribed there today for stroke recovery, anxiety disorders, and cognitive decline. Unlike stimulants (which flood the brain with dopamine) or sedatives (which suppress neuronal activity), these peptides work by upregulating the brain's own growth and repair factors. Semax stimulates the production of BDNF — brain-derived neurotrophic factor — a protein critical for learning, memory, and neuronal survival. Selank modulates the GABA system, the brain's primary calming pathway, producing anxiolytic effects without the sedation or dependence risk of benzodiazepines. A key practical advantage: both are administered as nasal sprays, bypassing the need for injections.
What People Research This For
- →Reducing anxiety and stress without sedation or dependence risk
- →Improving focus, attention, and working memory
- →BDNF upregulation for neuroprotection and neuroplasticity research
- →Combined Semax + Selank stack: Semax for cognitive sharpness, Selank for calm
- →Studying recovery mechanisms after neurological events (based on Russian clinical use)
- →Alternatives to benzodiazepines for anxiety research models
Pros & Cons
Effects Timeline
Based on published study timelines. Human extrapolation is approximate — individual results vary.
Anxiolytic effects of Selank are measurable within hours in animal models. BDNF protein increases from Semax are detectable at 24–72 hours post-dose in rodent studies. Self-researchers commonly report noticeable mood and focus effects within 3–7 days of consistent use.
Scientific Overview
Semax and Selank are synthetic peptides developed from ACTH and tuftsin respectively, with substantial preclinical and limited clinical evidence for nootropic and anxiolytic effects. Both peptides are administered primarily via intranasal spray due to direct transport along the olfactory nerve to central nervous system structures. Research focuses on upregulation of BDNF (brain-derived neurotrophic factor) and NGF (nerve growth factor), modulation of the GABAergic system, and regulation of monoamine neurotransmitters.
Mechanism of Action
Semax (MEHFPGP) is an ACTH(4-7) analogue that upregulates BDNF and NGF expression in the hippocampus and cortex, enhances dopaminergic and serotonergic tone, and reduces oxidative stress markers. Selank (TKPRPGP) is a tuftsin analogue that modulates GABAergic transmission (particularly GABA-A receptor subunit expression), suppresses IL-6 and TNF-α, and reduces anxiety indices in multiple validated behavioural paradigms.
Administration Methods
Dissolve lyophilised peptide in sterile saline to working concentration. Use calibrated nasal atomiser (MAD Nasal or equivalent) for consistent droplet size (30–100 µm).
0.1% solution (1 mg/mL)
Intranasal route enables direct olfactory-bulb transport, bypassing the blood-brain barrier. This is the primary route in human volunteer studies.
Reconstitute in sterile saline. Dose volume ≤ 0.2 mL per injection site in mice.
100–500 µg/mL
SC injection is used in rodent studies where intranasal administration is technically challenging. Plasma and CSF pharmacokinetics differ substantially from intranasal.
Research Protocols
Escape latency (seconds), platform quadrant dwell time during probe trial, BDNF mRNA (qPCR) in hippocampal tissue at sacrifice
Open-arm time (%), open-arm entries (%), serum corticosterone (ELISA), hippocampal BDNF protein (Western blot)
Hippocampal and prefrontal BDNF protein (ELISA), TrkB phosphorylation (Western blot), open-field locomotion (to control for sedation)
Key Published Studies
Selank affects the expression of genes that modulate the balance between anxiety and depression
2010Selank significantly upregulated genes involved in GABA-A receptor subunit expression and BDNF in rat prefrontal cortex after 5-day intranasal treatment, correlating with anxiolytic behaviour in EPM and light-dark box tests.
Semax, an ACTH4-10 analogue, affects the expression of BDNF and its receptor TrkB
2006Intranasal Semax produced a 2.5–3× increase in BDNF mRNA and protein in the hippocampus and frontal cortex of healthy rats at 24 and 72 hours post-administration.
Expected Outcomes
Based on the weight of published preclinical evidence. Outcomes may vary depending on model, dose, and administration route.
- ✓Upregulation of hippocampal BDNF and NGF (2–3× increase over vehicle at 14 days)
- ✓Reduced escape latency in Morris Water Maze (spatial memory improvement)
- ✓Increased open-arm time in Elevated Plus Maze (anxiolytic effect)
- ✓Reduced serum corticosterone under stress conditions
- ✓Enhanced TrkB receptor phosphorylation (BDNF receptor activation)
- ✓No significant sedation or locomotor impairment (open-field test)
Safety Considerations
- ⚠Both peptides have demonstrated excellent tolerability in published rodent and human volunteer studies.
- ⚠Intranasal administration requires nasal epithelium integrity; avoid in animals with rhinitis.
- ⚠Semax has been studied in post-stroke patients; extrapolating from disease models to healthy animals requires consideration of baseline neurotrophic tone.
- ⚠Not approved as therapeutic agents. Research use only.
Frequently Asked Questions
Why is intranasal the preferred route for Semax and Selank?
Intranasal delivery exploits the olfactory nerve pathway for direct CNS transport, achieving CSF concentrations significantly higher than equivalent IV doses. Both peptides are rapidly degraded peripherally, making direct CNS delivery critical for central effects.
How do Semax and Selank differ mechanistically?
Semax primarily drives BDNF/NGF expression and enhances monoaminergic (dopamine, serotonin) signalling — making it more relevant to cognitive enhancement and neuroprotection research. Selank acts predominantly on the GABAergic system and cytokine regulation, making it more relevant to anxiety and neuroimmune research.
Practical Notes for Self-Researchers
How do I use a nasal spray for Semax or Selank correctly?
Dissolve the lyophilised peptide in sterile saline to 0.1% (1 mg/mL) in a clean nasal atomiser. Clear nasal passages first. Spray into one nostril while gently inhaling — this facilitates olfactory nerve transport. Alternate nostrils between doses. Store reconstituted solution at 4°C and use within 14 days. Note: pump atomisers (MAD Nasal style) deliver more consistent droplet size than squeeze bottles.
Can I use Semax and Selank together?
Self-researchers frequently combine them: Semax for cognitive enhancement and BDNF upregulation, Selank for anxiety reduction and GABAergic modulation. They work via different mechanisms with no known adverse interactions. A common protocol in the research community is Semax in the morning and Selank in the evening, though no human clinical data exists to validate this specific approach.
How quickly should I expect to notice effects, and how long do they last?
In animal studies, Selank's anxiolytic effects are measurable within the first hour. Semax BDNF upregulation builds over 24–72 hours. Many self-researchers report noticing mood and focus improvements within the first week of consistent daily use. Effects appear to require ongoing administration — they are not persistent after stopping, unlike some nootropics.
Source Peptides for Your Research
Compare Japan-accessible peptide vendors on purity, testing, Japan shipping, and price per mg.